Cargando…
Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy
Toll-like receptor 5 (TLR5) is considered an attractive target for anticancer immunotherapy. TLR5 agonists, bacterial flagellin and engineered flagellin derivatives, have been shown to have potent antitumor and metastasis-suppressive effects in multiple animal models and to be safe in both animals a...
Autores principales: | Mett, V, Komarova, E A, Greene, K, Bespalov, I, Brackett, C, Gillard, B, Gleiberman, A S, Toshkov, I A, Aygün-Sunar, S, Johnson, C, Karasik, E, Bapardekar-Nair, M, Kurnasov, O V, Osterman, A L, Stanhope-Baker, P S, Morrison, C, Moser, M T, Foster, B A, Gudkov, A V |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5799711/ https://www.ncbi.nlm.nih.gov/pubmed/28967901 http://dx.doi.org/10.1038/onc.2017.346 |
Ejemplares similares
-
A deimmunized and pharmacologically optimized Toll-like receptor 5 agonist for therapeutic applications
por: Mett, Vadim, et al.
Publicado: (2021) -
First-in-human study of anticancer immunotherapy drug candidate mobilan: safety, pharmacokinetics and pharmacodynamics in prostate cancer patients
por: Eremina, Natalia V., et al.
Publicado: (2020) -
Superior cancer preventive efficacy of low versus high dose of mTOR inhibitor in a mouse model of prostate cancer
por: Antoch, Marina P., et al.
Publicado: (2020) -
Toll-like receptor-5 agonist Entolimod broadens the therapeutic window of 5-fluorouracil by reducing its toxicity to normal tissues in mice
por: Kojouharov, Bojidar M., et al.
Publicado: (2014) -
The Toll-Like Receptor 5 Agonist Entolimod Mitigates Lethal Acute Radiation Syndrome in Non-Human Primates
por: Krivokrysenko, Vadim I., et al.
Publicado: (2015)